176 related articles for article (PubMed ID: 12652335)
21. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
23. Accuracy of fluorodeoxyglucose-positron emission tomography for diagnosis of single bone metastasis: comparison with bone scintigraphy.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
J Comput Assist Tomogr; 2007; 31(5):812-9. PubMed ID: 17895798
[TBL] [Abstract][Full Text] [Related]
24. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
[TBL] [Abstract][Full Text] [Related]
25. 18Fluoro-deoxyglucose positron emission tomography evaluation of benign versus malignant osteochondromas: preliminary observations.
Feldman F; Vanheertum R; Saxena C
J Comput Assist Tomogr; 2006; 30(5):858-64. PubMed ID: 16954943
[TBL] [Abstract][Full Text] [Related]
26. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
27. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
28. [F-18 FDG positron emission tomography in diagnosis and follow-up of patients with musculoskeletal tumors].
Dobrowolskij D; Niggemeyer O; Jenicke L; Bruns J
Orthopade; 2002 Sep; 31(9):921-9. PubMed ID: 12232712
[TBL] [Abstract][Full Text] [Related]
29. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
[TBL] [Abstract][Full Text] [Related]
30. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.
Hickeson M; Yun M; Matthies A; Zhuang H; Adam LE; Lacorte L; Alavi A
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1639-47. PubMed ID: 12458399
[TBL] [Abstract][Full Text] [Related]
31. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET/CT for diagnosis of primary ovarian cancer.
Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
[TBL] [Abstract][Full Text] [Related]
33. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
[TBL] [Abstract][Full Text] [Related]
35. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
[TBL] [Abstract][Full Text] [Related]
36. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
37. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
38. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
Costantini DL; Vali R; Chan J; McQuattie S; Charron M
AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
[TBL] [Abstract][Full Text] [Related]
39. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
40. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]